At the crossroads of innovation and equity, Josette Gbemudu and Merck are helping rewrite the narrative for breast cancer ...

Later this month, the Food and Drug Administration is widely expected to approve a groundbreaking twice-yearly injection to ...

Sanofi picked up Blueprint Medicines in a deal worth up to $9.5 billion. Bristol Myers Squibb will pay $1.5 billion upfront ...

Alvotech and Dr. Reddy's will co-develop a biosimilar to Keytruda, aiming to expand global access to cancer treatment alternatives.

Alvotech (NASDAQ:ALVO) and Dr. Reddy’s Laboratories (NYSE:RDY) have entered into a collaboration and license agreement to ...

Discover the major highlights from ASCO 2025, according to researchers and drug developers who attended the convention.

New hope is on the horizon in the fight against cancer. At this year’s American Society of Clinical Oncology (ASCO) annual ...

Drugmakers unveil cancer drug data at the ASCO annual meeting, while Amazon Pharmacy announces new features for caregivers, ...

Detailed price information for Gilead Sciences Inc (GILD-Q) from The Globe and Mail including charting and trades.

Annual Meeting of the American Society of Clinical Oncology (ASCO), this year held in Chicago, Illinois from May 30 to June 2 ...

Detailed price information for Gilead Sciences Inc (GILD-Q) from The Globe and Mail including charting and trades.

Biontech SE and Bristol Myers Squibb Co. are teaming up to develop Biontech’s bispecific antibody targeting PD-L1 and VEGF-A, BNT-327, in a deal possibly worth over $11 billion. The companies will ...